PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
41.18%
R&D growth 50-75% of RVPH's 71.75%. Bruce Berkowitz would examine spending effectiveness.
22.12%
G&A growth less than half of RVPH's 105.21%. David Dodd would verify if efficiency advantage is structural.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.03%
Operating expenses growth less than half of RVPH's 79.21%. David Dodd would verify sustainability.
35.03%
Total costs growth less than half of RVPH's 79.21%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
14.84%
D&A growth while RVPH reduces D&A. John Neff would investigate differences.
-35.35%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-35.03%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-15.72%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-37.55%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.55%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-34.88%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-34.88%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
2.03%
Share count reduction below 50% of RVPH's 2.75%. Michael Burry would check for concerns.
2.03%
Diluted share reduction below 50% of RVPH's 2.75%. Michael Burry would check for concerns.